Capnia Inc (CAPN) : Vivo Capital reduced its stake in Capnia Inc by 0.13% during the most recent quarter end. The investment management company now holds a total of 7,456,984 shares of Capnia Inc which is valued at $7,121,420 after selling 9,368 shares in Capnia Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Capnia Inc makes up approximately 1.71% of Vivo Capital’s portfolio.
Other Hedge Funds, Including , Sabby Management reduced its stake in CAPN by selling 29,284 shares or 5.52% in the most recent quarter. The Hedge Fund company now holds 501,240 shares of CAPN which is valued at $478,684. Capnia Inc makes up approx 0.16% of Sabby Management’s portfolio. Blackrock Investment Management sold out all of its stake in CAPN during the most recent quarter. The investment firm sold 326 shares of CAPN which is valued $311.Vanguard Group Inc boosted its stake in CAPN in the latest quarter, The investment management firm added 8,155 additional shares and now holds a total of 60,966 shares of Capnia Inc which is valued at $58,223.Blackrock Fund Advisors boosted its stake in CAPN in the latest quarter, The investment management firm added 64 additional shares and now holds a total of 880 shares of Capnia Inc which is valued at $840.
Capnia Inc closed down -0.02 points or -1.94% at $1.01 with 13,951 shares getting traded on Thursday. Post opening the session at $1.01, the shares hit an intraday low of $1 and an intraday high of $1.0286 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Capnia Inc. develops medical diagnostics and therapeutics based on its technology for precision metering of gas flow. The Company’s diagnostic product CoSense aids in the diagnosis of hemolysis in neonates. The Company is applying its research and development efforts to additional diagnostic products based on its Sensalyze Technology Platform a portfolio of methods and devices which enables CoSense and can be applied to detect a variety of analytes in exhaled breath. The Company’s therapeutic technology involves the use of metered nasal carbon dioxide (CO2) for the potential treatment of various diseases. Serenz is the Company’s allergy therapeutic product candidate. It also launched new initiatives for the development of this technology for the treatment of trigeminally mediated pain disorders such as cluster headache and trigeminal neuralgia.